Novavax (NVAX) Net Equity Issued and Repurchased (2010 - 2024)

Novavax's Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $256.4 million for Q2 2024.

• On a quarterly basis, Net Equity Issued and Repurchased rose 313.66% year-over-year to $256.4 million in Q2 2024; TTM through Mar 2025 was $256.4 million, a 48.99% increase from a year earlier, with the FY2024 full-year figure at $263.3 million, down 26.92% from the prior year.
• Net Equity Issued and Repurchased grew to $256.4 million in Q2 2024 per NVAX's latest filing, from $6.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $564.9 million in Q1 2021 and bottomed at $1.5 million in Q2 2020.
• The 5-year median for Net Equity Issued and Repurchased is $179.4 million (2022), against an average of $192.6 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 49900.0% in 2020 and tumbled 68.24% in 2022, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $428.6 million in 2020, then soared by 31.81% to $564.9 million in 2021, then sank by 87.63% to $69.8 million in 2022, then jumped by 47.82% to $103.2 million in 2023, then jumped by 148.34% to $256.4 million in 2024.
• Per Business Quant, the three latest NVAX Net Equity Issued and Repurchased figures stand at $256.4 million (Q2 2024), $6.9 million (Q1 2024), and $103.2 million (Q4 2023).